ABCC7 p.Ile556Val
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 12167682
[PubMed]
Groman JD et al: "Variant cystic fibrosis phenotypes in the absence of CFTR mutations."
No.
Sentence
Comment
71
MUTATION IDENTIFIED BY SCREENING FOR COMMON MUTATIONS MUTATION IDENTIFIED BY DNA SEQUENCING NO. OF PATIENTS ∆F508 5T* 3 ∆F508 D1152H 2 ∆F508 2789+2insA 2 ∆F508 R117C 2 ∆F508 D110H 1 ∆F508 2789+5G→A 1 ∆F508 P205S 1 ∆F508 L967S 1 ∆F508 I1027T 1 ∆F508 L206W 1 ∆F508 T1053I and 5T 1 ∆F508 V920M and 5T 1 ∆F508 R1070W 1 ∆F508 D579G 1 ∆F508 P67L 1 ∆F508 2811G→T†‡ 1 G85E F191V† 1 R117H G103X and 5T 1 I148T I556V 1 G542X R1162L 1 W1282X D1152H 1 None L138ins and 3272-26 A→G 1 None G463D† and 5T 1 None F693L and 5T 1 ∆F508 None 6 G551D None 1 W1282X None 1 None 5T 4 None 2307insA 1 None L997F 1 None V520I 1 None None 30 in Subject II-2 in Family 1.
X
ABCC7 p.Ile556Val 12167682:71:548
status: NEW
PMID: 12952861
[PubMed]
Lee JH et al: "A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases."
No.
Sentence
Comment
74
CFTR genetic variants analyzed in this study Variations found by TDGS Most common worldwide disease-causing mutations Reported disease-associated microsatellite À8G/C (50 UTR)a R117H (exon 4) T5-7,9 (IVS 8) (16) I125T (exon 4)b 621 þ 1G > T (intron 4) E217G (exon 6a)b F508del (exon 10) 1059C > T (exon 7, A309)a 1717-1G > A (intron 10) M470V (exon 10)b G542X (exon 11) I556V (exon 11)b G551D (exon 11) 2694T/G (exon 14a, T854)b R553X (exon 11) Q1352H (exon 22)b R1162X (exon 19) R1453W (exon 24)b W1282X (exon 20) N1303K (exon 21) Mutation names and nucleotide numbers are presented according to the Cystic Fibrosis Genetic Analysis Consortium (CFGAC; www.genet.sickkids.on.ca/).
X
ABCC7 p.Ile556Val 12952861:74:380
status: NEW107 Frequency of CFTR gene variants in the Korean population Variation Genotype Group (number) Healthy control (n ¼ 117) Bronchiectasis (n ¼ 47) Pancreatitis (n ¼ 28) Diallelic -8G/C þ/þ 105 44 22 þ/Àa 12 3 6 R117H þ/þ 116 47 28 þ/À 1 0 0 I125T þ/þ 116 46 27 þ/À 1 1 1 E217G þ/þ 114 43 27 þ/À 3 4b 1 1059C > T þ/þ 117 47 27 (A309) þ/À 0 0 1 M470V þ/þ 23 3 6 þ/À 52 28 14 À/À 42 16 8 I556V þ/þ 111 45 28 þ/À 6 2 0 2694T/G þ/þ 41 16 8 (T854) þ/À 51 27 14 À/À 25 4 6 Q1352H þ/þ 116 43 24 þ/À 1 4* 4** R1453W þ/þ 115 46 28 þ/À 2 1 0 Microsatellite T5-7,9 5/7 4 6* 2 (IVS 8) 6/7 0 1 0 7/7 110 39*c 26 7/9 3 1 0 Differences between control and disease groups were analyzed by a chi-square test. When an expected cell value was less than 5, Fisher`s exact test was used.
X
ABCC7 p.Ile556Val 12952861:107:524
status: NEW114 Haplotype assembly Allele ID -8G/C R117H I125T E217G 1059C/T T5-7,9 M470V I556V 2694T/G Q1352H R1453W Group a M470V-2694T/G background Control, n (%) Bronchiectasis, n (%) Pancreatitis, n (%) 1 G R I E C WTb V I T Q R 121 (51.7) 47 (50.0) 24 (42.9) 2-1 2 G R I E C WT M I G Q R 78 (33.3) 25 (26.6) 18 (32.1) 1-2 3 C R I E C WT M I G Q R 11 (4.7) 3 (3.2) 5 (8.9) 1-2 4 G R I E C WT V I T H R 1 (0.4) 4 (4.3)* 4 (7.1)** 2-1 5 G R I E C 5 V I T Q R 2 (0.9) 5 (5.4)* 1 (1.8) 2-1 6 G R I G C WT M I G Q R 3 (1.3) 4 (4.3)c 1 (1.8) 1-2 7 G R I E C WT V V T Q R 5 (2.1) 2 (2.2) 0 (0.0) 2-1 8 G R I E C WT V I G Q R 4 (1.7) 1 (1.0) 0 (0.0) 2-2 9 G R I E C 5 M I G Q R 2 (0.9) 1 (1.0) 1 (1.8) 1-2 10 G R I E C WT M I G Q W 2 (0.9) 1 (1.0) 0 (0.0) 1-2 11 G R T E C WT V I T Q R 1 (0.4) 1 (1.0) 1 (1.8) 2-1 12 G R I E C WT M I T Q R 2 (0.9) 0 (0.0) 0 (0.0) 1-1 13 C R I E C WT V I G Q R 1 (0.4) 0 (0.0) 0 (0.0) 2-2 14 G H I E C WT V V T Q R 1 (0.4) 0 (0.0) 0 (0.0) 2-1 15 C R I E T WT M I G Q R 0 (0.0) 0 (0.0) 1 (1.8) 1-2 Total 234 (100.0) 94 (100.0) 56 (100.0) Haplotypes were assembled using a software based on the Bayesian algorithm (Haplotyper) (7).
X
ABCC7 p.Ile556Val 12952861:114:74
status: NEW134 Compared with WT, Po was significantly reduced in I556V (by 34%), Q1352H (by 55%), and R1453W (by 78%).
X
ABCC7 p.Ile556Val 12952861:134:50
status: NEW137 Therefore, it was concluded that the decreased current density in the whole cell ClÀ current of E217G (Fig. 3C) was due to the decreased membrane expression, and those of I556V and R1453W were due to the decreased Po.
X
ABCC7 p.Ile556Val 12952861:137:176
status: NEW176 Characteristics of CFTR mutants selected for functional studies Name Nucleotide change Exon Domain Evolutionary conservationa Possible disease associationb E217G 782A >G 6a EC2 b, h, r CF with pancreatic sufficiency (Polish), Panbronchiolitis (Japanese) I556V 1798A >G 11 NBD1 All seven species Chronic bronchitis (French) Q1352H 4188G > C 22 NBD2 All seven species CBAVD (Japanese), Panbronchiolitis (Japanese) R1453W 4489C > T 24 IC10 b, h, m, r, s Panbronchiolitis (Japanese) a Evolutionary conservations are compared in CFTR genes of bovine (b), dogfish (d), human (h), mouse (m), rabbit (r), sheep (s), and xenopus (x).
X
ABCC7 p.Ile556Val 12952861:176:254
status: NEW259 The mutagenic primers were as follows: E217G, 50 -CTC CTC ATG GGG CTA ATC TGG GGG TTG TTA CAG GCG TCT G-30 M470V, 50 -CTG GAG CAG GCA AGA CTT CAC TTC TAA TGG TGA TTA TGG GAG-30 ; I556V, 50 -AGT GGA GGT CAA CGA GCA AGA GTT TCT TTA GCA AGG TGA AT-30 ; Q1352H, 50 -CCT AAG CCA TGG CCA CAA GCA CTT GAT GTG CTT GGC TAG-30 ; R1453W, 50 -GTG AAG CTC TTT CCC CAC TGG AAC TCA AGC AAG TGC AAG TCT-30 .
X
ABCC7 p.Ile556Val 12952861:259:179
status: NEW
PMID: 14998948
[PubMed]
Danziger KL et al: "Improved detection of cystic fibrosis mutations in infertility patients with DNA sequence analysis."
No.
Sentence
Comment
85
Cauc. Het. * DF508/R117H Mutation/mutation Yesd 7 CBAVD Asian-Indian Het. Negative Het. V456A Mutationc No 8 CBAVD Asian Negative * Het. Q1352H Mutation Nod 9 CBAVD Asian Negative * Negative No mutation detected Yes 10 CBAVDb N.E. Cauc./ Asian/Ashkenazi Negative * I556V/2752±26A®G Mutation/mutation Nod 11 CBAVD Hispanic Homozygous * Het. W1098C Mutation Nod 12 CBAVD Asian Negative Negative Het. 3499+25C®G Variant of unknown signi®cance No 13 CUAVD Hispanic Negative * Negative No mutation detected Yes 14 CBAVDb N.E. Cauc. Negative * Negative No mutation detected Yes 15 Idiopathic obstruction Asian-Indian Negative * Het. I807M Mutationc Nod 16 Idiopathic obstruction N.E. Cauc. Het. * Het. DF508 Mutation Yesd *Analysis not done.
X
ABCC7 p.Ile556Val 14998948:85:265
status: NEW121 Mutations and variants of unknown signi®cance detected in 16 patients with CAVD Detection method 31 common mutation panel and poly T analysis Sequence method and poly T analysis Mutations 5T 7 7 DF508 2 2 R117H 1 1 P750L ± 1 V201M ± 1 Q1352H ± 1 I556V ± 1 2752±26A®G ± 1 W1098C ± 1 I807M ± 1 V456A ± 1 V520I ± 1 Variants of unknown signi®cance 1717±4A®G ± 1 3601±3C®A ± 1 3499+25C®G ± 1 Total 10 22 the vas deferens is particularly susceptible to the decreased levels of CFTR protein product.
X
ABCC7 p.Ile556Val 14998948:121:266
status: NEW
PMID: 16126774
[PubMed]
Morea A et al: "Gender-sensitive association of CFTR gene mutations and 5T allele emerging from a large survey on infertility."
No.
Sentence
Comment
76
This test involved nine subjects from the infertile group, revealing the occurrence of the following rare mutations: E217G, T1054A, W356X, D443Y and 3667insTC in males and L997F and R297Q in females and 29 subjects from the control, in which we found: A1009T, D110Y, E826K, G1069R, G1130A, G194V, I556V, L320F, M348K, M82V, P1290T, R117C, R352W, R74W, S42F, S660T, S911R, S912L, T1086A, T582S, V920L and Y89C.
X
ABCC7 p.Ile556Val 16126774:76:300
status: NEW
PMID: 16339147
[PubMed]
Jurkuvenaite A et al: "Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis."
No.
Sentence
Comment
183
His other allele is the I556V mutation.
X
ABCC7 p.Ile556Val 16339147:183:24
status: NEW
PMID: 17329263
[PubMed]
Ratbi I et al: "Detection of cystic fibrosis transmembrane conductance regulator (CFTR) gene rearrangements enriches the mutation spectrum in congenital bilateral absence of the vas deferens and impacts on genetic counselling."
No.
Sentence
Comment
95
C)] þ [I556V] 1 Apparent homozygosity 3 0-3 1 [R117H] þ [R117H] 1 1 [D110H] þ [D110H] 1 [R74W;D1270 N] þ [R74W;D1270 N] 1 Total 61 57-75 4 F508del, 2221dupA, as well as variants at the IVS8(TG)m(T)n polymorphic site.
X
ABCC7 p.Ile556Val 17329263:95:12
status: NEW
PMID: 17539902
[PubMed]
Chang MC et al: "Spectrum of mutations and variants/haplotypes of CFTR and genotype-phenotype correlation in idiopathic chronic pancreatitis and controls in Chinese by complete analysis."
No.
Sentence
Comment
97
These mutations include I556V, G to A 3849145, N287Y, I125T, E217G, S895N, G1O69R, and Q1352H that have been found in patients with CP or CBAVD (http://www.genet.
X
ABCC7 p.Ile556Val 17539902:97:24
status: NEW109 (%) in ICP Controls (%) I556V Exon 11 A to G 1798 Amino acid substitution 7 (8.9) 2 (1) IVS8-5T Intron 8 deletaion of 2T between 1342-12 and 1342-6 Aberrant splicing 6 (7.7) 14 (7) G to A 3849145 Intron 19 G to A at 3849145 mRNA splicing defect 3 (3.8) 2 (1) N287Y Exon 6b A to T 991 Amino acid substitution 2 (2.6) 00 (0) I125T Exon 4 T to C 506 Amino acid substitution 1 (1.3) 00 (0) E217G Exon 6a A to G 782 Amino acid substitution 1 (1.3) 00 (0) S895N Exon 15 G to A 2816 Missense mutation 1 (1.3) 00 (0) G1O69R Exon 17b G to A 3337 Amino acid substitution 1 (1.3) 00 (0) Q1352H Exon 22 G to C at 4188 Amino acid substitution 0 (0.0) 1 (0.5) ICP, idiopathic chronic pancreatitis.
X
ABCC7 p.Ile556Val 17539902:109:24
status: NEW157 All our mutations are belonging to Ômild` mutations compatible with previous studies (6), including I556V, G to A 3849145, I125T, E217G, N287Y, S895N, G1O69R, and Q1352H.
X
ABCC7 p.Ile556Val 17539902:157:105
status: NEW158 Among them, we found a significantly higher accumulation of the I556V allele in our patients with ICP.
X
ABCC7 p.Ile556Val 17539902:158:64
status: NEW159 I556V that was originally identified in patients with moderate pulmonary disease and sufficient pancreatic function (33) was found in seven patients; the frequency of I556V in chronic pancreatitis (7/78, 8.9%) was significantly (p , 0.0001) higher than that of controls (2/200, 1%).
X
ABCC7 p.Ile556Val 17539902:159:0
status: NEWX
ABCC7 p.Ile556Val 17539902:159:167
status: NEW171 I556V, I125T and Q1352H are reported to be associated chronic pulmonary disease from Singapore (35).
X
ABCC7 p.Ile556Val 17539902:171:0
status: NEW
PMID: 17981921
[PubMed]
Chang YT et al: "Association of cystic fibrosis transmembrane conductance regulator (CFTR) mutation/variant/haplotype and tumor necrosis factor (TNF) promoter polymorphism in hyperlipidemic pancreatitis."
No.
Sentence
Comment
8
The CFTR gene mutations were all Ile556Val.
X
ABCC7 p.Ile556Val 17981921:8:33
status: NEW75 The only CFTR mutation hot spot was in codon 556 (Ile556Val), and of the 13 patients with this substitution, 12 had HLP.
X
ABCC7 p.Ile556Val 17981921:75:50
status: NEW115 In contrast, the Ile556Val CFTR missense mutation was the most common mutation in our HLP patients.
X
ABCC7 p.Ile556Val 17981921:115:17
status: NEW116 The Ile556Val mutation has a mild effect among CFTR mutations and appears to be associated with the pancreatitis phenotype (28).
X
ABCC7 p.Ile556Val 17981921:116:4
status: NEW118 Ile556Val was also reported to be associated with chronic pulmonary disease in Singapore (30).
X
ABCC7 p.Ile556Val 17981921:118:0
status: NEW119 The frequency of the Ile556Val mutation in our HLP patients was 26.1% (12 of 46).
X
ABCC7 p.Ile556Val 17981921:119:21
status: NEW120 Interestingly, Ile556Val was also the most frequent CFTR mutation in our patients with idiopathic chronic pancreatitis (15).
X
ABCC7 p.Ile556Val 17981921:120:15
status: NEW121 The frequency of the Ile556Val CFTR mutation in our healthy control population was about 1% (1 in 200) (15), similar to the frequency in our HTG patients without HLP (1.3%, 1 of 80).
X
ABCC7 p.Ile556Val 17981921:121:21
status: NEW122 Because the TG concentrations in our chronic pancreatitis cohort were within the TG reference interval, HTG is not likely associated with the CFTR Ile556Val mutation.
X
ABCC7 p.Ile556Val 17981921:122:147
status: NEW123 Furthermore, the mean TG concentration in our HLP patients with the Ile556Val mutation was not significantly different from that of patients without the Ile556Val mutation.
X
ABCC7 p.Ile556Val 17981921:123:68
status: NEWX
ABCC7 p.Ile556Val 17981921:123:153
status: NEW
PMID: 18304229
[PubMed]
Sakamoto H et al: "Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation associated with a congenital bilateral absence of vas deferens."
No.
Sentence
Comment
8
A CFTR gene mutation of I556V was found.
X
ABCC7 p.Ile556Val 18304229:8:24
status: NEW20 However, a CFTR gene mutation of I556V (exon11, 556A → G) in one allele was detected by genomic DNA extraction from the peripheral blood sample and amplification of exons 10 and 11 in the CFTR gene by polymerase chain reaction, followed by sequence analysis, which was analyzed after obtaining an informed consent.
X
ABCC7 p.Ile556Val 18304229:20:33
status: NEW29 In our case, we analyzed exons 10 and 11 in the CFTR gene to evaluate the possibility of transmission of CF to newborn because common mutations such as D508, DI507, 551D, G542X, and R553X associated with CF in Caucasians was frequently identified in these exons.1 I556V found in the present case is a mutation initially reported in a French male who had asthma-like bronchopathy and chronic diarrhea, which was recently identified in 10% to 15% of Asians irrespective of chronic respiratory diseases.7 CBAVD is suggested based on the identification of azoospermia with either normal-sized or slightly smaller testes, a non-palpable vas deferens, characteristic imaging findings and the physical and biological properties of the ejaculate: small volume (<2 mL), low pH (<7), and low fructose concentration.1 Most CBAVD patients have defects in the derivatives of the wolffian duct system presenting as an absence of the distal portion of the epididymides, seminal vesicle atrophy or absence, and the absence of the vas deferens by scrotal and transrectal ultrasonography.4,5,9 However, not all men with CBAVD have extensive abnormalities of the derivatives of the wolffian duct system.5,9 Previous studies showed that seminal vesicle anomalies with either agenesis, hypoplasia, or cystic dysplasia occur in 36% to 92% of men with CBAVD.4-6,9 Jarvi et al. showed that all CBAVD patients with at least one CFTR gene mutation had abnormalities of both the seminal vesicles and ampulla of the vas deferens and that 50% of CBAVD patients with no detectable CFTR gene mutation had a normal ampulla of the vas deferens and seminal vesicles.5 Therefore, the frequency and severity of the wolffian duct malformations in the CBAVD patients may be related directly to the CFTR genotype.5 Moreover, previous studies report that 11% to 21% of CBAVD patients had renal agenesis.6,9 Renal agenesis has been reported to occur predominately in men with a congenital absence of vas deferens (CAVD) without CFTR gene mutations.9 However, Casales et al. showed CFTR gene mutations in five of 16 CAVD patients (bilateral absence in six, and unilateral absence in 10) with renal agenesis.6 In addition, CAVD may also be associated with cryptorchidism and inguinal hernia.6 The prevalence of the CFTR gene mutation carrier in the Japanese population may be approximate to that of the Caucasian.1,2 Moreover, infertile patients with CBAVD can now be treated by assisted reproduction technology.1 Genetic counseling may be recommended for any couple attempting assisted reproduction technology when the man has defects of the vas deferens.1-3,8 References 1 Jarzabek K, Zbucka M, Pepiñski W et al. Cystic fibrosis as a cause of infertility.
X
ABCC7 p.Ile556Val 18304229:29:264
status: NEW
No.
Sentence
Comment
49
However, the CFTR I556V CFmild-variant mutation was observed in 12 of 46 (26.1%) patients with AP, and only in 1 of 80 (1.3%) hypertriglyceridemic patients without AP ( p < 0.0001).
X
ABCC7 p.Ile556Val 20059346:49:18
status: NEW
PMID: 20233062
[PubMed]
van de Vosse E et al: "Distribution of CFTR variations in an Indonesian enteric fever cohort."
No.
Sentence
Comment
8
We identified 12 variants in, or adjacent to, the exons: 1 novel variant (L435V), 3 known mutations (N287K, I556V, Q1352H), and 8 known polymorphisms.
X
ABCC7 p.Ile556Val 20233062:8:108
status: NEW72 Variations Identified Once in 25 Sequenced Samples Variation SNP a Observed frequency Reported frequency of minor allele -8G1C in exon 1, 5`UTR rs1800501 1 in 50 (2%) 4.4% in Chinese, a 3.4% in Japanese, a 0%-4.5% in Europeans, a 0%-2.2% in Africans a 861C1G in exon 6b, leading to N287K NA 1 in 50 (2%) Found once in a Taiwanese CBAVD patient [12] 1303C1G in exon 9, leading to L435V NA 1 in 50 (2%) Novel variation, no data available 1666A1G in exon 11, leading to I556V NA 1 in 50 (2%) 2.6% in Koreans [11], 5.0% in Singapore Chinese [21] 3870A1G in exon 20, silent rs1800130 1 in 50 (2%) 0% in Chinese and in Japanese, a 0%-4.2% in Europeans, a 11.9%-21.2% in Africans a NOTE. CBAVD, congenital bilateral absence of the vas deferens; NA, not available; SNP, single-nucleotide polymorphism.
X
ABCC7 p.Ile556Val 20233062:72:467
status: NEW134 Five of these were identified only once and were therefore not further analyzed in the full cohort, 2 of which, N287K and I556V, had been reported before as mutations and 1 of which, L435V, was identified for the first time.
X
ABCC7 p.Ile556Val 20233062:134:124
status: NEW136 I556V had been identified in Korean individuals and molecularly proven to be defective [11].
X
ABCC7 p.Ile556Val 20233062:136:0
status: NEW
PMID: 20879059
[PubMed]
Kim KW et al: "Association between cystic fibrosis transmembrane conductance regulator gene mutations and susceptibility for childhood asthma in Korea."
No.
Sentence
Comment
53
CFTR Genetic Variations Analyzed in This Study Name Nucleotide change Exon Consequence Reference - 8G / C G to C at 125 5` UTR sequence variation 9 Q98R A to G at 425 Exon 4 Gln to Arg at 98 8 I125T T to C at 506 Exon 4 Ile to Thr at 125 9 E217G A to G at 782 Exon 6a Glu to Gly at 217 9 Q220X C to T at 790 Exon 6a Gln to Stop at 220 7, 8 A309A C or G at 1059 Exon 7 Sequence variation 9 TG repeat TG10-13 IVS 8 Splicing 9 T repeat T5-9 IVS 8 Splicing 9 M470V A or G at 1540 Exon 10 Met to Val at 470 9 I556V A to G at 1798 Exon 11 Ile to Val at 556 9 T854T T to G at 2694 Exon 14a Sequence variation 9 Q1291X C to T at 4003 Exon 20 Gln to Stop at 1291 9 Q1352H G to C at 4188 Exon 22 Gln to His at 1352 9 R1453W C to T at 4489 Exon 24 Arg to Trp at 1453 9 CFTR,cysticfibrosistransmembraneconductanceregulator.
X
ABCC7 p.Ile556Val 20879059:53:504
status: NEWX
ABCC7 p.Ile556Val 20879059:53:533
status: NEW69 Frequency of CFTR Genetic Variations in Non-Asthma and Asthma Group Variants Non-asthma (n) Asthma (n) p value* - 8G / C G / G 39 37 0.466 G / C 8 11 C / C 1 0 E217G A / A 48 46 0.247 A / G 0 2 M470V A / A 8 10 0.858 A / G 25 23 G / G 15 15 I556V A / A 42 45 0.276 A / G 4 3 T854T T / T 15 16 0.639 T / G 26 22 G / G 7 10 Q1352H G / G 46 46 0.383 G / C 2 2 R1453W C / C 47 46 0.500 C / T 0 1 Microsatellite TG repeat (IVS 8)� W / W� 10 12 0.119 W / M 27 18 M / M 10 18 T repeat (IVS 8) 5 / 7 2 1 0.141 6 / 7 0 1 7 / 7 44 42 7 / 9 1 4 CFTR,cysticfibrosistransmembraneconductanceregulator.
X
ABCC7 p.Ile556Val 20879059:69:241
status: NEW
PMID: 22483971
[PubMed]
Li H et al: "Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) in Chinese patients with congenital bilateral absence of vas deferens."
No.
Sentence
Comment
77
Lastly, we have observed previously reported mutations and polymorphisms (p.E217G, p.R347H, p.V470M, p.R553X, p.I556V, p.T854T, p.G970D, p.P1290P, p.Q1352H, p.Q1643Q, 744-5delGATT, IVS8-T5) (Supplementary Table 1).
X
ABCC7 p.Ile556Val 22483971:77:112
status: NEW81 There was one patient homozygous for the missense mutation (I556V/I556V), but most other patients carried a missense or splicing mutation on at least one allele.
X
ABCC7 p.Ile556Val 22483971:81:60
status: NEWX
ABCC7 p.Ile556Val 22483971:81:66
status: NEW106 The CFTR mutation p.I556V has been reported in the project of 1000 Genomes, and identified in Japanese infertility patients and French patients with asthma-like bronchopathy and chronic diarrhea [38,39].
X
ABCC7 p.Ile556Val 22483971:106:20
status: NEWX
ABCC7 p.Ile556Val 22483971:106:31
status: NEW107 However, our study detected an I556V gene mutation on both alleles in one Chinese CBAVD patient; this was located in the domain which functions as the ATP-binding domain.
X
ABCC7 p.Ile556Val 22483971:107:31
status: NEW119 △F508 R117H Mutation genotypes IVS8-Tn n (%) Two mutations detected Neg Neg I556V/I556V 7T/7T 1(1.3) Neg Neg I556V/1209+2 G-C 5T/7T 1(1.3) Neg Neg I556V/726delATT 5T/5T 1(1.3) Neg Neg I556V/- 5T/5T 1(1.3) Neg Neg I556V/- 5T/7T 1(1.3) Neg Neg G970D/- 5T/7T 1(1.3) Neg Neg C592F/- 5T/5T 1(1.3) Neg Neg 1209+1 G-C/- 5T/7T 1(1.3) Neg Neg R553X/- 5T/7T 1(1.3) Neg Neg Q1352H/- 5T/7T 1(1.3) Neg Neg S485C/- 5T/7T 1(1.3) Neg Neg A357T/- 5T/7T 1(1.3) Neg Neg E217G/- 5T/7T 1(1.3) Neg Neg R347H/- 5T/7T 1(1.3) Neg Neg G451K/- 5T/7T 1(1.3) Neg Neg L558S/- 5T/7T 1(1.3) Neg Neg 3635delT/Q1352H 7T/7T 1(1.3) Neg Neg A1136T/G970D 7T/7T 1(1.3) Neg Neg 870-1 G-C/- 5T/7T 1(1.3) Neg Neg 520-2 A-G/- 5T/7T 1(1.3) Neg Neg R419I/- 5T/7T 1(1.3) Neg Neg C491F/Q1643Q 7T/7T 1(1.3) Neg Neg Q1352H/- 5T/7T 1(1.3) Neg Neg R851X/- 5T/7T 1(1.3) Neg Neg P750L/G970D 7T/7T 1(1.3) One mutation detected Neg Neg -/- 5T/7T 2(2.7) Neg Neg -/- 5T/7T 3(4.1) Neg Neg -/- 5T/7T 5(6.8) Neg Neg -/- 5T/5T 2(2.7) Neg Neg -/- 5T/5T 1(1.3) Neg Neg G970D/- 7T/7T 2(2.7) Neg Neg D993Y/- 7T/7T 1(1.3) Neg Neg I556V/- 7T/7T 1(1.3) Neg Neg T388R/- 7T/7T 1(1.3) No mutation detected Neg Neg -/- 7T/7T 8(10.9) Neg Neg -/- 7T/7T 15(20.5) Neg Neg -/- 7T/9T 2(2.7) Neg Neg -/- 7T/7T 4(5.5) Neg: Negative.
X
ABCC7 p.Ile556Val 22483971:119:83
status: NEWX
ABCC7 p.Ile556Val 22483971:119:89
status: NEWX
ABCC7 p.Ile556Val 22483971:119:116
status: NEWX
ABCC7 p.Ile556Val 22483971:119:154
status: NEWX
ABCC7 p.Ile556Val 22483971:119:191
status: NEWX
ABCC7 p.Ile556Val 22483971:119:220
status: NEWX
ABCC7 p.Ile556Val 22483971:119:1071
status: NEW76 Lastly, we have observed previously reported mutations and polymorphisms (p.E217G, p.R347H, p.V470M, p.R553X, p.I556V, p.T854T, p.G970D, p.P1290P, p.Q1352H, p.Q1643Q, 744-5delGATT, IVS8-T5) (Supplementary Table 1).
X
ABCC7 p.Ile556Val 22483971:76:112
status: NEW80 There was one patient homozygous for the missense mutation (I556V/I556V), but most other patients carried a missense or splicing mutation on at least one allele.
X
ABCC7 p.Ile556Val 22483971:80:60
status: NEWX
ABCC7 p.Ile556Val 22483971:80:66
status: NEW105 The CFTR mutation p.I556V has been reported in the project of 1000 Genomes, and identified in Japanese infertility patients and French patients with asthma-like bronchopathy and chronic diarrhea [38,39].
X
ABCC7 p.Ile556Val 22483971:105:20
status: NEW118 b3;F508 R117H Mutation genotypes IVS8-Tn n (%) Two mutations detected Neg Neg I556V/I556V 7T/7T 1(1.3) Neg Neg I556V/1209+2 G-C 5T/7T 1(1.3) Neg Neg I556V/726delATT 5T/5T 1(1.3) Neg Neg I556V/- 5T/5T 1(1.3) Neg Neg I556V/- 5T/7T 1(1.3) Neg Neg G970D/- 5T/7T 1(1.3) Neg Neg C592F/- 5T/5T 1(1.3) Neg Neg 1209+1 G-C/- 5T/7T 1(1.3) Neg Neg R553X/- 5T/7T 1(1.3) Neg Neg Q1352H/- 5T/7T 1(1.3) Neg Neg S485C/- 5T/7T 1(1.3) Neg Neg A357T/- 5T/7T 1(1.3) Neg Neg E217G/- 5T/7T 1(1.3) Neg Neg R347H/- 5T/7T 1(1.3) Neg Neg G451K/- 5T/7T 1(1.3) Neg Neg L558S/- 5T/7T 1(1.3) Neg Neg 3635delT/Q1352H 7T/7T 1(1.3) Neg Neg A1136T/G970D 7T/7T 1(1.3) Neg Neg 870-1 G-C/- 5T/7T 1(1.3) Neg Neg 520-2 A-G/- 5T/7T 1(1.3) Neg Neg R419I/- 5T/7T 1(1.3) Neg Neg C491F/Q1643Q 7T/7T 1(1.3) Neg Neg Q1352H/- 5T/7T 1(1.3) Neg Neg R851X/- 5T/7T 1(1.3) Neg Neg P750L/G970D 7T/7T 1(1.3) One mutation detected Neg Neg -/- 5T/7T 2(2.7) Neg Neg -/- 5T/7T 3(4.1) Neg Neg -/- 5T/7T 5(6.8) Neg Neg -/- 5T/5T 2(2.7) Neg Neg -/- 5T/5T 1(1.3) Neg Neg G970D/- 7T/7T 2(2.7) Neg Neg D993Y/- 7T/7T 1(1.3) Neg Neg I556V/- 7T/7T 1(1.3) Neg Neg T388R/- 7T/7T 1(1.3) No mutation detected Neg Neg -/- 7T/7T 8(10.9) Neg Neg -/- 7T/7T 15(20.5) Neg Neg -/- 7T/9T 2(2.7) Neg Neg -/- 7T/7T 4(5.5) Neg: Negative.
X
ABCC7 p.Ile556Val 22483971:118:82
status: NEWX
ABCC7 p.Ile556Val 22483971:118:88
status: NEWX
ABCC7 p.Ile556Val 22483971:118:115
status: NEWX
ABCC7 p.Ile556Val 22483971:118:153
status: NEWX
ABCC7 p.Ile556Val 22483971:118:190
status: NEWX
ABCC7 p.Ile556Val 22483971:118:219
status: NEWX
ABCC7 p.Ile556Val 22483971:118:1070
status: NEW
PMID: 16678503
[PubMed]
Ngiam NS et al: "Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: a pilot study."
No.
Sentence
Comment
4
Results: Three missense mutations (I125T, I556V, and Q1352H) and 1 splice site variant (intron 8 12TG5T) were identified in a total of 10 patients, representing a combined mutant/variant allele frequency of 0.25.
X
ABCC7 p.Ile556Val 16678503:4:42
status: NEW78 Three missense mutations (I125T in exon 4, I556V in exon 11, and Q1352H in exon 22) and one splice site variant (intron 8 12TG5T) were identified among the patients.
X
ABCC7 p.Ile556Val 16678503:78:43
status: NEW90 Similarly, 3 severe asthma patients were heterozygous for the I556V mutation (21.4%), compared to 10% (4 of 40) in the normal controls, and an estimated population frequency of 12.5% (12 of 96).
X
ABCC7 p.Ile556Val 16678503:90:62
status: NEW93 Table 1 Frequency of CFTR gene variants in the Singaporean Chinese Variation Genotype Unselected population samples (n =93-96) Healthy controls (n =40) Severe asthma (n =14) Idiopathic bronchiectasis (n =6) I125T I125T/WT 2 1 0 2 WT/WT 94 39 14 4 I556V I556V/WT 12 4 3 0 WT/WT 84 36 11 6 Q1352H Q1352H/WT 4 1 2 0 WT/WT 91 39 12 6 12TG5T 12TG5T/Other 9 1 2 1 Other/Other 84 39 12 5 Table 2 CFTR gene variant allele frequency comparisons between patient and population and normal control groups Variation Allele Unselected population (n =186-192) Healthy controls (n =80) Severe asthma (n =28) P-value Idiopathic bronchiectasis (n =12) P-value I125T Variant 2 1 0 1.000a 2 0.018a,* Wild-type 190 79 28 1.000b 10 0.044b,* I556V Variant 12 4 3 0.415a 0 1.000a Wild-type 180 76 25 0.372b 12 1.000b Q1352H Variant 4 1 2 0.172a 0 1.000a Wild-type 186 79 26 0.163b 12 1.000b 12TG5T 12TG5T 9 1 2 0.640a 1 0.473a Other 177 79 26 0.164b 11 0.245b a P value for disease vs. unselected population.
X
ABCC7 p.Ile556Val 16678503:93:247
status: NEWX
ABCC7 p.Ile556Val 16678503:93:253
status: NEWX
ABCC7 p.Ile556Val 16678503:93:719
status: NEW121 The first description of I556V was made in a male French patient having atypical CF who was also compound heterozygous for another mutation, R31C in exon 2 [24].
X
ABCC7 p.Ile556Val 16678503:121:25
status: NEW123 One of his children inherited his I556V mutation, and had chronic bronchitis suggestive of CF, although the authors indicated that the diagnosis was not clear.
X
ABCC7 p.Ile556Val 16678503:123:34
status: NEW124 In the Korean study, I556V was shown to reduce the current density in the whole-cell chloride current by reducing the open probability of the channel [22].
X
ABCC7 p.Ile556Val 16678503:124:21
status: NEW139 The mutations were the I556V and the Q1352H mutations.
X
ABCC7 p.Ile556Val 16678503:139:23
status: NEW
PMID: 23523379
[PubMed]
Rechitsky S et al: "PGD for cystic fibrosis patients and couples at risk of an additional genetic disorder combined with 24-chromosome aneuploidy testing."
No.
Sentence
Comment
42
[1075C>A; 1079C>A] p.[Gln359Lys; Thr360Lys] Exon 8 1 1 1 4 1 1 R297Q c.890G>A p.Arg297Gln Exon 8 1 1 1 2 0 0 R347P c.1040G>C p.Arg347Pro Exon 8 3 5 2 4 1 1 T338I c.1013C>T p.Thr338Ile Exon 8 1 1 1 2 1 1 DF508 c.1521_1523delCTT p.Phe508del Exon 11 130 195 172 345 88 (4) 92 DI507 c.1519_1521delATC p.Ile507del Exon 11 1 5 5 11 2 1 Q493R c.1478A>G p.Gln493Arg Exon 11 5 5 2 2 2 2 1717-1G-A c.1585-1G>A - Intron 11 6 10 9 18 6 8 G542X c.1624G>T p.Gly542X Exon 12 14 17 15 34 10 10 G551S c.1651G>A p.Gly551Ser Exon 12 1 1 1 2 1 1 G551D c.1652G>A p.Gly551Asp Exon 12 12 22 19 33 7 8 I556V c.1666A>G p.Ile556Val Exon 12 1 2 2 4 1 1 R553X c.1657C>T p.Arg553X Exon 12 3 4 2 4 0 0 R560T c.1679G>C p.Arg560Thr Exon 12 1 1 1 2 1 2 1898+1G-A c.1766 &#b1; 1G>A - Intron 13 1 1 1 2 1 1 2184delA c.2052delA p.Lys684AsnfsX38 Exon 14 1 1 0 0 0 0 G622D c.1865G>A p.Gly622Asp Exon 14 1 1 1 3 0 0 N703S c.2108A>G p.Asn703Ser Exon 14 1 2 2 3 2 2 S737F c.2210C>T p.Ser737Phe Exon 14 1 1 0 0 0 0 2622+1G-A c.2490 &#b1; 1G>A - Intron 14 1 5 5 13 1 1 2752-26A-G c.2620-26A>G - Intron 15 1 2 2 4 0 0 2789+5G-A c.2657 &#b1; 5G>A - Intron 16 3 5 4 8 0 0 3120G-A c.2988G>A - Exon 18 2 2 1 2 1 0 3067-72del c.3067_3072del p.Ile1023_Val1024del Exon 19 1 1 1 1 0 0 I1027T c.3080T>C p.Ile1027Thr Exon 19 1 1 1 1 0 0 L997F c.2991G>C p.Leu997Phe Exon 19 1 2 2 4 1 (1) 0 M1028R c.3083T>G p.Met1028Arg Exon 19 1 1 1 2 1 2 F1052V c.3154T>G p.Phe1052Val Exon 20 1 1 0 0 0 0 Y1092X c.3276C>A p.Tyr1092X Exon 20 1 2 1 2 1 1 A1136T c.3406G>A p.Ala1136Thr Exon 21 1 2 1 2 1 0 D1152H c.3454G>C p.Asp1152His Exon 21 3 7 7 15 1 1 3659 del C c.3528delC p.Lys1177SerfsX15 Exon 22 2 4 3 7 3 3 R1162X c.3484C>T p.Arg1162X Exon 22 1 3 2 5 2 2 S1235R c.3705T>G p.Ser1235Arg Exon 22 2 3 3 5 2 1 3849+10kbC>T c.3717 &#b1; 12191C>T - Intron 22 2 4 4 5 0 0 W1282X c.3846G>A p.Trp1282X Exon 23 15 20 20 42 11 11 N1303K c.3909C>G p.Asn1303Lys Exon 24 9 12 11 24 4 5 Q1352H c.4056G>C p.Gln1352His Exon 25 1 1 1 1 1 1 Total 265 404 345 685 172 (6a ) 175 Values are n unless otherwise stated.
X
ABCC7 p.Ile556Val 23523379:42:578
status: NEWX
ABCC7 p.Ile556Val 23523379:42:596
status: NEW
PMID: 23810505
[PubMed]
Prach L et al: "Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California."
No.
Sentence
Comment
59
of parents receiving CFTR mutation testing Diagnosis/ status Study participants with positive NBS results 1 W, H 83.5 p.F508del* c.2554_2555insTy 7T/9T 2 CF 2 H 527.0 p.F508del c.-877C>T p.F1107L 7T/9T 0 CF 3 W 86.5 p.F508del p.V562Iy c.-837T>Cy 5Tyz /9T 1 CF 4 H 222.3 p.F508del p.I556V c.1278delC NA 0 CF 5 H, O 93.5 p.F508del* c.-152G>Cy 7T/9T 2 CF 6 W, H, B, O 95.4 p.F508del* p.L323Py 5Tyz /9T 2 CF 7 H 70.5 p.F508del p.L32M 7T/9T 0 CF 8 W 209.5 p.F508del c.2883_2886dupGTCA 9T/9T 0 CF 9 H 155.7 p.F508del* c.2349_2350insT 7T/9T 1 CF 10 O 146.8 p.F508del* c.3718-24G>Ay 5Tyx /9T 2 CF 11 B 99.4 p.A559T* p.L206Wy c.-448A>G* 7T/9T 2 CF 12 W, H 90.3 p.P205S p.K114del 7T/7T 0 CF 13 H 69.7 p.P205S p.K114del 7T/7T 0 CF 14 H 82.9 c.274-1G>A* c.-602A>Ty 7T/7T 2 CF 15 W 106.6 p.F508del* c.-461A>Gy c.-983A>T* 7T/9T 2 CRMS 16 W, B 83.9 p.F508del c.4243-5C>T 5T*x /9T 1 CRMS 17 W 81.5 p.F508del* p.I1027T* p.Y325C 7T/9T 2 CRMS 18 H 70.7 p.F508del c.-967T>C 9T/9T 0 CRMS 19 W, H 62.4 p.F508del* c.-635A>G 7T/9T 1 CRMS 20 H 65.4 p.F508dely c.2490 &#fe; 14G>T* 7T/9T 2 CRMS 21 W 69.3 p.F508del* c.744-15T>Cy 7T/9T 2 CRMS 22 W, H, O 66.2 p.F508del p.D249Y 7T/9T 0 CRMS 23 H 94.8 p.F508del p.R811S 7T/9T 0 CRMS 24 W 75.8 p.F508del* p.H1375Ny 7T/9T 2 CRMS 25 H 63.0 p.F508del p.L136P 7T/9T 0 CRMS 26 W, O 63.0 p.F508del* p.M1140L 7T/9T 1 CRMS 27 W, O 91.7 p.F508del p.V1198M 9T/9T 0 CRMS 28 H 69.3 p.F508dely c.1767-13T>G* 7T/9T 2 CRMS 29 H 108.8 p.F508del p.V1322L 7T/9T 0 CRMS 30 H 96.4 p.F508dely p.C76R* 7T/9T 2 CRMS 31 H 69.0 c.3140-26A>G c.-510G>A* 7T/7T 1 CRMS 32 H 100.2 p.G542X c.-684G>A* 7T/9T 1 CRMS 33 H 84.1 c.1153_1154insAT* c.-730A>Gy 7T/7T 2 CRMS 34 H 62.9 c.1973_ 1985del13insAGAAA* p.D112Gy 7T/7T 2 CRMS 35 H 116.7 c.3744delA* p.T887P 7T/7T 1 CRMS 36 B 73.3 c.2988 &#fe; 1G>A c.-288G>C 7T/9T 0 CRMS 37 H 93.5 p.R75X c.3367 &#fe; 3A>C 7T/7T 0 CRMS 38 W, H 81.4 c.3717 &#fe; 12191C>T* c.-769A>Gy 7T/7T 2 CRMS 39 W 79.0 c.3717 &#fe; 12191C>Ty p.R668Cy p.T1396P* 7T/9T 2 CRMS 40 H 87.3 c.274-1G>A p.F315S 7T/7T 0 CRMS 41 H 79.7 p.G542X c.869 &#fe; 8G>T 7T/9T 0 CRMS 42 O 79.8 p.R553X p.T1478R 7T/7T 0 CRMS 43 H 70.5 p.A559T* c.-448A>G* 7T/7T 2 Carrier 44 B 76.2 p.A559T* c.-448A>G* 7T/7T 1 Carrier 45 W, H 69.2 p.G85E* c.744-15T>C* 5Tyz /7T 2 Carrier 46 W 69.1 p.N1303K* c.2490 &#fe; 14G>A* 7T/9T 1 Carrier 47 W, O 111.7 p.F508del c.3963 &#fe; 6G>T 7T/9T 0 ND{ 48 W 80.1 p.F508del p.R1128G 7T/9T 0 ND{ (table continues) sequencing.
X
ABCC7 p.Ile556Val 23810505:59:282
status: NEW166 Participant 4 carried p.F508del, p.I556V, and novel variant c.1278delC.
X
ABCC7 p.Ile556Val 23810505:166:35
status: NEW168 It is surmised, however, that the frameshift mutation c.1278delC would be more deleterious than the missense mutation p.I556V.
X
ABCC7 p.Ile556Val 23810505:168:120
status: NEW
PMID: 23953609
[PubMed]
Lu S et al: "Different cystic fibrosis transmembrane conductance regulator mutations in Chinese men with congenital bilateral absence of vas deferens and other acquired obstructive azoospermia."
No.
Sentence
Comment
7
RESULTS Six heterozygous mutations (&#fe;/), I556V, M469V, E527N, F508del, S485C, and I558S, were found in 30 patients, and 1 homozygous mutation (&#fe;/&#fe;), I556V, was found in 1 patient.
X
ABCC7 p.Ile556Val 23953609:7:46
status: NEWX
ABCC7 p.Ile556Val 23953609:7:162
status: NEW9 Of these mutations, I556V was the most common type with 24 of 31 (77.4%).
X
ABCC7 p.Ile556Val 23953609:9:20
status: NEW10 In CBAVD group, 20 of 158 patients were identified with 6 different heterozygous mutations (I556V, M469V, E527N, F508del, S485C, and I558S) and 1 homozygous mutation (I556V).
X
ABCC7 p.Ile556Val 23953609:10:92
status: NEWX
ABCC7 p.Ile556Val 23953609:10:167
status: NEW12 In acquired obstructive group, 11 of 243 patients were identified with 2 different heterozygous mutations, I556V and M469V; the rate of mutations was 4.5%.
X
ABCC7 p.Ile556Val 23953609:12:107
status: NEW17 I556V is the major common type of CFTR mutations in Chinese patients with CBAVD.
X
ABCC7 p.Ile556Val 23953609:17:0
status: NEW50 (B) I556V mutation is indicated by arrow.
X
ABCC7 p.Ile556Val 23953609:50:4
status: NEW53 detected in 31 patients, including 30 cases of 6 different heterozygous mutations (I556V, M469V, E527N, F508del, S485C, and I558S) as positive for only 1 mutation (&#fe;/), and 1 case of homozygous mutations (I556V); the rate of CFTR mutations was 7.7%.
X
ABCC7 p.Ile556Val 23953609:53:83
status: NEWX
ABCC7 p.Ile556Val 23953609:53:210
status: NEW54 Of these mutations, I556V was the most common type with 24 of 31 (77.4%).
X
ABCC7 p.Ile556Val 23953609:54:20
status: NEW55 In CBAVD patients, 20 of 158 patients were identified with 6 different CFTR mutations, including 19 cases of 6 different heterozygous mutations (I556V, M469V, E527N, F508del, S485C, and I558S), 1 case of homozygous mutations (I556V); the rate of CFTR mutations was 12.7%.
X
ABCC7 p.Ile556Val 23953609:55:145
status: NEWX
ABCC7 p.Ile556Val 23953609:55:226
status: NEW56 In other obstructive azoospermia group, 2 different heterozygous CFTR mutations were identified in 11 of 243 patients, including 10 patients of I556V mutations and 1 of M469V mutations.
X
ABCC7 p.Ile556Val 23953609:56:144
status: NEW66 Frequency of different mutations types in 31 male patients Mutations Type Frequency I556V 24/31 (77.4%) M469V 3/31 (9.7%) E527N 1/31 (3.2%) F508del 1/31 (3.2%) L558S 1/31 (3.2%) S485C 1/31 (3.2%) Table 1.
X
ABCC7 p.Ile556Val 23953609:66:84
status: NEW67 Cystic fibrosis transmembrane conductance regulator gene mutations in 31 male patients Patient Number Age (y) Diagnosis Mutation Locus Mutation Alleles Change of Nucleotide Change of Amino Acid Chromosome 1 27 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 2 30 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 3 25 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 4 25 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 5 28 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 6 28 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 7 25 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 8 30 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 9 26 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 10 28 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 11 29 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 12 30 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 13 23 CBAVD I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 14 31 CBAVD I556V Homo (&#fe;/&#fe;) AA/AG Ile (ATT) to Val (GTT) 46XY 15 27 CBAVD M469V Hetero (&#fe;/) AA/AG Met (ATG) to Val (GTG) 46XY 16 27 CBAVD M469V Hetero (&#fe;/) AA/AG Met (ATG) to Val (GTG) 46XY 17 29 CBAVD E527N Hetero (&#fe;/) GG/AG Glu (GAA) to Lys (AAA) 46XY 18 33 CBAVD F508del Hetero (&#fe;/) Del TCT Deletion of Phe at 508 46XY 19 26 CBAVD L558S Hetero (&#fe;/) TT/TC Leu (TTA) to Ser (TCA) 46XY 20 35 CBAVD S485C Hetero (&#fe;/) AA/AT Ser (AGT) to Cys (TGT) 46XY 21 25 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 22 32 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 23 29 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 24 25 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 25 30 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 26 25 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 27 37 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 28 29 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 29 23 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 30 27 ObsA I556V Hetero (&#fe;/) AA/AG Ile (ATT) to Val (GTT) 46XY 31 27 ObsA M469V Hetero (&#fe;/) AA/AG Met (ATG) to Val (GTG) 46XY CBAVD, congenital bilateral absence of vas deferens; hetero, heterozygous; homo, homozygous; ObsA, obstructive azoospermia.
X
ABCC7 p.Ile556Val 23953609:67:216
status: NEWX
ABCC7 p.Ile556Val 23953609:67:284
status: NEWX
ABCC7 p.Ile556Val 23953609:67:352
status: NEWX
ABCC7 p.Ile556Val 23953609:67:420
status: NEWX
ABCC7 p.Ile556Val 23953609:67:488
status: NEWX
ABCC7 p.Ile556Val 23953609:67:556
status: NEWX
ABCC7 p.Ile556Val 23953609:67:624
status: NEWX
ABCC7 p.Ile556Val 23953609:67:692
status: NEWX
ABCC7 p.Ile556Val 23953609:67:760
status: NEWX
ABCC7 p.Ile556Val 23953609:67:829
status: NEWX
ABCC7 p.Ile556Val 23953609:67:898
status: NEWX
ABCC7 p.Ile556Val 23953609:67:967
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1036
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1105
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1593
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1661
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1729
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1797
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1865
status: NEWX
ABCC7 p.Ile556Val 23953609:67:1933
status: NEWX
ABCC7 p.Ile556Val 23953609:67:2001
status: NEWX
ABCC7 p.Ile556Val 23953609:67:2069
status: NEWX
ABCC7 p.Ile556Val 23953609:67:2137
status: NEWX
ABCC7 p.Ile556Val 23953609:67:2205
status: NEW72 Of these mutations, approximately 24 of 31 (77.4%) mutations were I556V, including 23 of heterozygous mutations and 1 of homozygous mutation.
X
ABCC7 p.Ile556Val 23953609:72:66
status: NEW75 I556V, other than F508del, might be the major mutation in Chinese patients.
X
ABCC7 p.Ile556Val 23953609:75:0
status: NEW76 Besides 1 I556V homozygous mutation observed, all other mutations were heterozygous mutations; they might be in correspondence with the clinical feature in these patients with CBAVD, which had no other CF syndrome such as lung or pancreatic diseases.
X
ABCC7 p.Ile556Val 23953609:76:10
status: NEW79 Such mutations would produce abnormally low levels of CFTR protein, which may cause obstruction of the vas deferens, but there may be sufficient protein to prevent from disease in other organs normally affected by CF.18 I556V found in the present cases is a mutation initially reported in a French man who had asthma-like bronchopathy and chronic diarrhea, which was recently identified in 10%-15% of Asians irrespective of chronic respiratory diseases.19 Because the I556V and M469V heterozygous mutations were all founded in CBAVD and obstructive azoospermia groups, they might not be special mutations for CBAVD.
X
ABCC7 p.Ile556Val 23953609:79:220
status: NEWX
ABCC7 p.Ile556Val 23953609:79:468
status: NEW81 I556V is the major common type of CFTR mutations in Chinese patients with CBAVD.
X
ABCC7 p.Ile556Val 23953609:81:0
status: NEW
PMID: 25492507
[PubMed]
Nakano E et al: "Targeted next-generation sequencing effectively analyzed the cystic fibrosis transmembrane conductance regulator gene in pancreatitis."
No.
Sentence
Comment
90
On average, 90.3 % of the coding region was successfully covered by C20 reads Table 2 Non-synonymous CFTR variants detected in this study Exon Non-synonymous variant Amino acid change dbSNP135 Genotype SIFT (score) PolyPhen-2 (score) Alcoholic CP (%) Idiopathic CP (%) Hereditary/ familial CP (%) 2 c.91C[T p.R31C rs1800073 CT D (0.012) PD (0.989) 0/46 (0) 3/121 (2.5) 0/26 (0) 2 c.92G[A p.R31H rs149353983 GA T (0.183) B (0.003) 0/46 (0) 1/121 (0.8) 0/26 (0) 4 c.374T[C p.I125T rs141723617 TC D (0.005) B (0.17) 0/46 (0) 2/121 (1.6) 1/26 (3.8) 10 c.1231A[G p.K411E - AG D (0.015) B (0.233) 0/46 (0) 1/121 (0.8) 0/26 (0) 11 c.1408G[A p.V470M rs213950 GA T (1) B (0) 21/46 (45.7) 65/121 (53.7) 11/26 (42.3) AA 5/46 (10.9) 19/121 (15.7) 1/26 (3.8) 12 c.1666A[G p.I556V rs75789129 AG T (0.536) B (0.334) 2/46 (4.3) 8/121 (6.6) 0/26 (0) GG 0/46 (0) 0/121 (0) 0/26 (0) 13 c.1753G[T p.E585X - GT - - 1/46 (2.2) 0/121 (0) 0/26 (0) 17 c.2869delC p.L957fs - - - 0/46 (0) 1/121 (0.8) 0/26 (0) 21 c.3468G[T p.L1156F rs139729994 GT T (0.163) PD (0.994) 2/46 (4.3) 10/121 (8.3) 2/26 (7.7) TT 1/46 (2.2) 0/121 (0) 0/26 (0) 25 c.4045G[A p.G1349S rs201686600 GA D (0) PD (1) 1/46 (2.2) 0/121 (0) 0/26 (0) 25 c.4056G[C p.Q1352H rs113857788 GC D (0) PD (1) 5/46 (10.9) 11/121 (9.1) 4/26 (15.4) CC 0/46 (0) 0/121 (0) 0/26 (0) 27 c.4357C[T p.R1453W rs4148725 CT D (0) PD (0.999) 3/46 (6.5) 6/121 (5.0) 1/26 (3.8) B benign, CP chronic pancreatitis, D damaging, PD probably damaging, T tolerated, SIFT Sorting Intolerant From Tolerant heterozygous form (Table 6).
X
ABCC7 p.Ile556Val 25492507:90:763
status: NEW100 There were no significant difference for any other non-synonymous or synonymous variants detected in the exons Table 3 Comparison of the non-synonymous variant frequencies between the patients with CP and controls Amino acid change Genotype All CP (%) HGVD (%) P value (vs. HGVD) All CP Alcoholic CP Nonalcoholic CP Idiopathic CP Hereditary/ familial CP p.R31C CT 3/193 (1.6) 12/1102 (1.1) 0.48 [0.99 0.41 0.18 [0.99 p.R31H GA 1/193 (0.5) 0 - - - - - p.I125T TC 3/193 (1.6) 5/1102 (0.5) 0.11 [0.99 0.057 0.15 0.13 p.K411E AG 1/193 (0.5) 0 - - - - - p.V470M GA 97/193 (50.3) 573/1199 (47.8) 0.66 0.57 0.68 0.38 0.12 AA 25/193 (13.0) 185/1199 (15.4) p.I556V AG 10/193 (5.2) 78/1150 (6.8) 0.70 0.79 0.81 [0.99 0.45 GG 0/193 (0) 3/1150 (0.3) p.E585X GT 1/193 (0.5) 0 - - - - - p.L957fs 1/193 (0.5) 0 - - - - - p.L1156F GT 14/193 (7.3) 45/1136 (4.0) 0.04 0.06 0.07 0.11 0.30 TT 1/193 (0.5) 1/1136 (0.1) p.G1349S GA 1/193 (0.5) 4/1094 (0.4) 0.56 0.19 [0.99 [0.99 [0.99 p.Q1352H GC 20/193 (10.4) 57/1153 (4.9) 0.009 0.12 0.037 0.17 0.062 CC 0/193 (0) 1/1153 (0.1) p.R1453W CT 10/193 (5.2) 42/1144 (3.7) 0.32 0.25 0.49 0.45 [0.99 CP chronic pancreatitis, HGVB Human Genetic Variation Database P values were determined versus HGVD by the Fisher`s exact test Table 4 Synonymous variants in the exons of the CFTR gene detected in this study Exon Synonymous variant Amino acid change dbSNP135 Genotype Alcoholic CP (%) Idiopathic CP (%) Hereditary/ familial CP (%) 4 c.372C[T p.G124= - CT 0/46 (0) 1/121 (0.8) 0/26 (0) 13 c.1731C[T p.Y577= rs55928397 CT 0/46 (0) 1/121 (0.8) 0/26 (0) 15 c.2562T[G p.T854= rs1042077 TG 20/46 (43.5) 69/121 (57.0) 12/26 (46.2) GG 6/46 (13.0) 18/121 (14.9) 0/26 (0) 23 c.3723C[A p.G1241= rs185065886 CA 1/46 (2.2) 0/121 (0) 0/26 (0) 25 c.3975A[G p.R1325= - AG 0/46 (0) 1/121 (0.8) 0/26 (0) 27 c.4254G[A p.E1418= - GA 0/46 (0) 1/121 (0.8) 0/26 (0) 27 c.4389G[A p.Q1463= rs1800136 GA 1/46 (2.2) 3/121 (2.5) 0/26 (0) CP chronic pancreatitis between all patients with CP and controls (Tables 3, 5).
X
ABCC7 p.Ile556Val 25492507:100:650
status: NEW114 Comprehensive analysis by targeted NGS enabled us to identify novel and Table 5 Comparison of the synonymous variant frequencies between the patients with CP and controls Synonymous variant Genotype All CP (%) HGVD (%) P value (vs. HGVD) All CP Alcoholic CP Nonalcoholic CP Idiopathic CP Hereditary/ familial CP c.C372T CT 1/193 (0.5) 0 - - - - - c.1731C[T CT 1/193 (0.5) 0 - - - - - c.2562T[G TG 101/193 (52.3) 528/1154 (45.8) 0.22 0.81 0.11 0.045 0.033 GG 24/193 (12.4) 181/1154 (15.7) c.3723C[A CA 1/193 (0.5) 3/671 (4.5) [0.99 0.23 [0.99 [0.99 [0.99 c.3975A[G AG 1/193 (0.5) 0 - - - - - c.4254G[A GA 1/193 (0.5) 0 - - - - - c.4389G[A GA 4/193 (2.1) 40/1112 (3.6) 0.48 [0.99 0.53 0.81 [0.99 AA 0/193 (0) 1/1112 (0.1) CP chronic pancreatitis, HGVD Human Genetic Variation Database P values were determined against HGVD by the Fisher`s exact test Table 6 Total CFTR sequencing results of patients carrying rare non-synonymous CFTR variants a Pancreatitis-associated mutations in the PRSS1, SPINK1, CTRC, and CPA1 genes Case# Etiology Age at onset Rare variant Additional non-synonymous variants c.1210-34TG(9_13) c.1210-12T(5_9) Mutation in other pancreatitis susceptibility genesa A1 Idiopathic 34 p.R31C/- p.R1453W/- TG11/TG11, 7T/7T - A2 Idiopathic 8 p.R31C/- - TG11/TG12, 7T/7T - A3 Idiopathic 16 p.R31C/- - TG11/TG12, 7T/7T - A4 Idiopathic 10 p.R31H/- - TG11/TG12, 7T/7T - A5 Idiopathic 16 p.I125T/- p.L1156F/- TG11/TG12, 7T/7T CTRC p.R29Q/- A6 Idiopathic 2 p.I125T/- - TG11/TG12, 7T/7T - A7 Hereditary 28 p.I125T/- p.R1453W/- TG11/TG12, 7T/7T - A8 Idiopathic 19 p.K411E/- p/L1156F/- TG11/TG12, 7T/7T - A9 Alcoholic 28 p.E585X/- p.I556V/- TG11/TG11, 7T/7T - A10 Idiopathic 21 p.L957fs/- p.Q1352H/- TG11/TG12, 7T/7T - A11 Alcoholic 40 p.G1349S/- - TG11/TG11, 7T/7T - rare variants in the CFTR gene.
X
ABCC7 p.Ile556Val 25492507:114:1637
status: NEW123 Two of the three patients carrying this variant had other non-synonymous variants (p.I556V and p.R1453W).
X
ABCC7 p.Ile556Val 25492507:123:85
status: NEW151 Sequence capture eliminates the necessity of setting up hundreds of PCR, instead allowing for parallel Table 8 Total CFTR sequencing results of patients with SPINK1, PRSS1, CTRC, or CPA1 mutations Case# Etiology CFTR variantsa c.1210-34TG(9_13) c.1210-12T(5_9) SPINK1 PRSS1 CTRC CPA1 B1 Familial p.Q1352H/- TG11/TG12, 7T/7T p.N34S/p.N34S B2 Idiopathic - TG12/TG12, 7T/7T p.N34S/p.N34S B3 Idiopathic - TG11/TG12, 7T/7T p.N34S/p.N34S B4 Idiopathic p.L1156F/-, p.Q1352H/- TG11/TG11, 7T/7T p.N34S/- B5 Idiopathic p.Q1352H/- TG11/TG12, 7T/7T p.N34S/- B6 Idiopathic p.Q1352H/- TG11/TG12, 7T/7T p.N34S/- B7 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B8 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B9 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B10 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B11 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B12 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B13 Idiopathic - TG11/TG12, 7T/7T p.N34S/- B14 Alcoholic - TG12/TG13, 5T/7T p.N34S/- B15 Idiopathic - TG11/TG12, 7T/7T p.N34S/IVS3?2T[C B16 Idiopathic p.R1453W/- TG11/TG11, 7T/7T p.N34S/IVS3?2T[C B17 Idiopathic - TG11/TG12, 7T/7T IVS3?2T[C/IVS3?2T[C B18 Idiopathic - TG11/TG12, 7T/7T IVS3?2T[C/IVS3?2T[C B19 Hereditary p.I125T/-, p.L1156F/- TG11/TG12, 5T/7T IVS3?2T[C/- B20 Familial p.L1156F/- TG11/TG12, 7T/7T IVS3?2T[C/- B21 Idiopathic - TG11/TG12, 7T/7T IVS3?2T[C/- B22 Alcoholic p.Q1352H/- TG11/TG12, 7T/7T IVS3?2T[C/- B23 Alcoholic - TG11/TG12, 7T/7T IVS3?2T[C/- B24 Idiopathic - TG11/TG12, 7T/7T p.P45S/- B25 Idiopathic - TG12/TG12, 7T/7T IVS3?2T[C/- p.R122H/- B26 Hereditary TG11/TG12, 7T/7T p.R122H/- B27 Idiopathic p.I556V/- TG11/TG12, 7T/7T p.N29I/- B28 Idiopathic p.I125T/-, p.L1156F/- TG11/TG12, 7T/7T p.R29Q/- B29 Idiopathic - TG11/TG12, 7T/7T p.T368_Y369ins20/- Nine patients had the non-synonymous CFTR variants, which are probably damaging based on the SIFT or the PolyPhen-2 prediction The p.I556V variant appeared to be benign based on the SIFT or the PolyPhen-2 prediction Case B28 is the same as A5 in Table 6 a We excluded the p.V470M variant from the list because of its similar frequencies in patients and controls enrichment of target regions in a single experiment.
X
ABCC7 p.Ile556Val 25492507:151:1578
status: NEWX
ABCC7 p.Ile556Val 25492507:151:1861
status: NEW
PMID: 25869325
[PubMed]
Chang MC et al: "Cystic fibrosis transmembrane conductance regulator gene variants are associated with autoimmune pancreatitis and slow response to steroid treatment."
No.
Sentence
Comment
8
Results: A total of 28.1% (25/89) of the AIP patients carried 26 CFTR variants, including nine with I556V, seven with 5T, four with S42F, two with I125T, and one each with R31C, R553X, S895N, and G1069R.
X
ABCC7 p.Ile556Val 25869325:8:100
status: NEW112 The identified variants included I556V in nine patients, 5T in seven, S42F in four, I125T in two, and R31C, R553X, S895N, and G1069R each in one patient (Table 1).
X
ABCC7 p.Ile556Val 25869325:112:33
status: NEW140 AIP (n = 89) CFTR variants n = 26 % in AIP % with variant I556V 9 10.1% 34.6% 5 T 7 7.9% 26.9% S42F 4 4.5% 15.4% I125T 2 2.2% 7.7% R31C 1 1.1% 3.8% R553X 1 1.1% 3.8% S895T 1 1.1% 3.8% G1069R 1 1.1% 3.8% Table 2 Comparison of patients with and without CFTR variants in 89 patients with autoimmune pancreatitis.
X
ABCC7 p.Ile556Val 25869325:140:58
status: NEW149 The most common CFTR variant in AIP patients was I556V (34.6%), followed by the T5 allele in intron 8 (26.9%) and S42F (15.4%).
X
ABCC7 p.Ile556Val 25869325:149:49
status: NEW152 The CFTR variant I556V was the most common variant in HLP [20], ICP [19], and AIP patients in our studies.
X
ABCC7 p.Ile556Val 25869325:152:17
status: NEW
PMID: 26089335
[PubMed]
Kondo S et al: "Functional characteristics of L1156F-CFTR associated with alcoholic chronic pancreatitis in Japanese."
No.
Sentence
Comment
11
Six variants (E217G, I556V, M470V, L1156F, Q1352H, and R1453W) were identified in the coding region of the CFTR gene.
X
ABCC7 p.Ile556Val 26089335:11:21
status: NEW57 Six CFTR variants, c.650Ab0e;G, p.Glu217Gly (E217G); c.1666Ab0e;G, p.Ile556Val (I556V); M470V; L1156F; Q1352H; and R1453W, were detected.
X
ABCC7 p.Ile556Val 26089335:57:75
status: NEWX
ABCC7 p.Ile556Val 26089335:57:86
status: NEW132 Six variants (E217G, I556V, M470V, L1156F, Q1352H, and R1453W) were identified in coding regions of the CFTR gene (Table 2).
X
ABCC7 p.Ile556Val 26089335:132:21
status: NEW135 The allele frequencies of E217G, I556V, and M470V were not different among groups.
X
ABCC7 p.Ile556Val 26089335:135:33
status: NEW141 The allele frequencies of polymorphisms in the coding regions of CFTR gene ACP ICP NS n 140 36 360 E217G (exon 6a) Glu 137 (97.9) 36 (100) 354 (98.3) Gly 3 (2.1) 0 (0) 6 (1.7) M470V (exon 10) Met 60 (42.9) 14 (38.9) 143 (39.7) Val 80 (57.1) 22 (61.1) 217 (60.3) I556V (exon 11) Ile 138 (98.6) 36 (100) 348 (96.7) Val 2 (1.4) 0 (0) 12 (3.3) L1156F (exon 18) Leu 133 (95.0) 35 (97.2) 358 (99.4) Phe 7 (5.0)* 1 (2.8) 2 (0.6) Q1352H (exon 22) Gln 129 (92.1) 35 (97.2) 353 (98.1) His 11 (7.9)* 1 (2.8) 7 (1.9) R1453W (exon 24) Arg 138 (98.6) 32 (88.9) 353 (98.1) Trp 2 (1.4) 4 (11.1)* 7 (1.9) Values are no.
X
ABCC7 p.Ile556Val 26089335:141:262
status: NEW